The latest announcement is out from Graphite Bio (GRPH).
On March 14, 2024, Graphite’s stockholders approved significant decisions, including issuing common stock to LENZ OpCo stockholders, a change of control resulting from a merger, and the issuance of common stock to PIPE Investors. This merger was completed on March 21, 2024, when Graphite also underwent a reverse stock split and rebranded to LENZ Therapeutics, Inc. The merger agreement facilitated the exchange of LENZ OpCo shares for LENZ Therapeutics common stock and the conversion of options and warrants. Post-merger, the company has over 25 million shares of common stock outstanding and will trade on Nasdaq under the ticker “LENZ.” This strategic move is described in detail in the company’s SEC filings and is accompanied by forward-looking statements regarding the company’s future product development, commercialization strategies, and financial projections.
See more data about GRPH stock on TipRanks’ Stock Analysis page.
